公开(公告)号：WO2017190096A1

公开(公告)日：2017-11-02

申请号：PCT/US2017/030279

申请日：2017-04-28

Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED

Inventor： RIVKEES, Scott, A. ,  WENDLER, Christopher ,  CHANG, Lung-ji

IPC: A61K48/00 ,  C12N15/00 ,  C12N5/16 ,  C07H21/04

CPC classification number: C07K16/2869 ,  A61K35/17 ,  A61K48/005 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70596 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/70 ,  C12N5/16 ,  C12N9/6472 ,  C12N15/86 ,  C12N2740/16043 ,  C12Y304/22062

Abstract: Aspects of the disclosure relate to chimeric antigen receptors (CARs) comprising an antigen binding domain (e.g., anti-TSHR), transmembrane domain (e.g., CD28), and a cytoplasmic domain (e.g., CD27, CD- 137, etc.) and a safety mechanism comprising an inducible apoptosis trigger. In some aspects, the disclosure relates to use of the CARs in T cells, compositions, kits and methods for the treatment of thyroid cancers.

Abstract translation: 公开内容的方面涉及包含抗原结合结构域（例如抗TSHR），跨膜结构域（例如CD28）和细胞质结构域（例如CD27）的嵌合抗原受体（CAR） CD-137等）和包含诱导型细胞凋亡触发因素的安全机制。 在一些方面，本公开涉及在T细胞，用于治疗甲状腺癌的组合物，试剂盒和方法中使用CAR。

公开(公告)号：WO2020243659A1

公开(公告)日：2020-12-03

申请号：PCT/US2020/035441

申请日：2020-05-29

Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED

Inventor： RIVKEES, Scott, A. ,  SRIVASTAVA, Arun

IPC: C07K16/28 ,  C12N15/864

Abstract: Disclosed herein are compositions and methods for continuous AAV-based delivery of blocking anti-TSHR antibodies to a subject having a thyroid disease. The present disclosure is based, at least in part, on the realization that blocking anti-TSHR antibodies may be delivered in a continuous manner using rAAV, e.g., rAAVS, to effectively block the stimulating effects of TSAbs or TSH on TSHR, thereby blocking or reducing the synthesis of thyroid hormone. By blocking or reducing the synthesis of thyroid hormone, the presently described methods and compositions for rAAV-based delivery of blocking anti-TSHR antibodies (e.g., K1-70) may be used to treat thyroid diseases, including Graves' disease, Graves' orbitopathy, and thyroid cancer without the requirement of repeated administrations.

公开(公告)号：WO2019217834A1

公开(公告)日：2019-11-14

申请号：PCT/US2019/031746

申请日：2019-05-10

Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED

Inventor： RIVKEES, Scott, A.

IPC: A61K31/395 ,  A61K31/54 ,  A61K31/5415 ,  C07D285/00 ,  C07D285/26 ,  C07D285/28

Abstract: The invention is directed towards compounds, methods of stimulating myelination, stimulating proliferation of oligodendrocytes (OLs) or stimulating oligodendrocyte precursor cells and methods of treating diseases, disorders or symptoms thereof.